Right from the day of the announcement, Russia’s COVID vaccine ‘Sputnik V’ which is claimed to be the world’s first has been under the bad light while scientists across the world raised concerns over the safety. Many claimed that Russia is taking an enormous risk by going ahead with a vaccine that has not been tested rigorously on humans to ascertain its safety and efficacy.
Amidst which, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF) on Thursday stated that they are looking for a partnership with India for producing COVID-19 vaccine which has been on the controversy tabs.
“The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India,” said Dmitriev in an online press briefing. According to the Gamaleya Institute, Russia is ready to produce over 500 million doses per year across the country like India, Brazil, South Korea, Cuba, and a number of other countries that have extended production facilities
While the full-scale production of the vaccine is expected to begin in September, it can be noted that India is one of the 20 countries that have expressed a willingness to be part of Sputnik V’s Phase-3 clinical trials.
Hailed as effective by Russian authorities and scientists, Sputnik V vaccine consists of two shots that use different versions of adenoviruses — virus types, some of which cause the common cold — that the manufacturers have engineered to carry the gene for the surface protein of SARS-CoV-2 that causes COVID-19.